33
The company produces AstraZeneca's corona vaccine and is developing its own vaccine against the pandemic.
The South Korean pharmaceutical company SK Bioscience will raise the equivalent of around 1.1 billion euros from the planned IPO. The vaccine developer is allocating its shares at 65,000 won (48.25 euros) each and thus at the upper end of the offering range. The company produces AstraZeneca's corona vaccine and is developing its own vaccine against the pandemic.
